Margitta Worm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4047105/publications.pdf

Version: 2024-02-01

491 papers 29,559 citations

82 h-index 150 g-index

596 all docs

596
docs citations

596 times ranked 20277 citing authors

#	Article	IF	CITATIONS
1	Anaphylaxis knowledge gaps and future research priorities: AÂconsensus report. Journal of Allergy and Clinical Immunology, 2022, 149, 999-1009.	2.9	21
2	EAACI guidelines: Anaphylaxis (2021 update). Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 357-377.	5.7	193
3	Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placeboâ€controlled, randomized, phase III clinical trial (ECZTRA 7)*. British Journal of Dermatology, 2022, 186, 440-452.	1.5	42
4	Development and validation of the food allergy severity score. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1545-1558.	5.7	19
5	Proposal of 0.5Âmg of protein/100Âg of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper. Allergy: European Journal of Allergy and Clinical Immunology. 2022. 77. 1736-1750.	5.7	21
6	Atopic dermatitis and depressive symptoms. Results of the German national AD Registry TREATgermany. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
7	Response to "Targeted Use of Placebo Effects Decreases Experimental Itch in Atopic Dermatitis Patients: A Randomized Controlled Trial― Clinical Pharmacology and Therapeutics, 2022, 111, 541-541.	4.7	O
8	The <scp>panâ€JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16â€week randomized phase <scp>Ilb</scp> trial*. British Journal of Dermatology, 2022, 187, 42-51.	1.5	28
9	Is benzyl alcohol a significant contact sensitizer?. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 866-872.	2.4	3
10	COVIDâ€19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicalsâ€"EAACI recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2313-2336.	5.7	12
11	Allergen immunotherapy during the COVIDâ€19 pandemicâ€"A survey of the German Society for Allergy and Clinical Immunology. Clinical and Translational Allergy, 2022, 12, e12134.	3.2	6
12	S3 Guideline Allergy Prevention. Allergologie, 2022, 6, 61-97.	0.1	52
13	Mast cells instruct keratinocytes to produce thymic stromal lymphopoietin: Relevance of the tryptase/protease-activated receptor 2 axis. Journal of Allergy and Clinical Immunology, 2022, 149, 2053-2061.e6.	2.9	14
14	Tolerance induction through non-avoidance to prevent persistent food allergy (TINA) in children and adults with peanut or tree nut allergy: rationale, study design and methods of a randomized controlled trial and observational cohort study. Trials, 2022, 23, 236.	1.6	7
15	Tolerance induction through early feeding to prevent food allergy in infants with eczema (TEFFA): rationale, study design, andÂmethods of a randomized controlled trial. Trials, 2022, 23, 210.	1.6	8
16	Serological profiling reveals hsa-miR-451a as a possible biomarker of anaphylaxis. JCI Insight, 2022, 7, .	5.0	9
17	Perception of the coronavirus pandemic by patients with atopic dermatitis – Results from the TREATgermany registry. JDDG - Journal of the German Society of Dermatology, 2022, 20, 45-57.	0.8	3
18	Practical patch testing in allergic contact dermatitis in children. Alergologia, 2022, 1, 6.	0.1	0

#	Article	IF	Citations
19	Risk factors for severe reactions in food allergy: Rapid evidence review with metaâ€analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2634-2652.	5.7	50
20	Genetic Associations and Differential mRNA Expression Levels of Host Genes Suggest a Viral Trigger for Endemic Pemphigus Foliaceus. Viruses, 2022, 14, 879.	3.3	4
21	German S1 guideline: Contact dermatitis. JDDG - Journal of the German Society of Dermatology, 2022, 20, 712-734.	0.8	10
22	S1â€Leitlinie Kontaktekzem. JDDG - Journal of the German Society of Dermatology, 2022, 20, 711-734.	0.8	4
23	Diversities of allergic pathologies and their modifiers: Report from the second DGAKI-JSA meeting. Allergology International, 2022, 71, 310-317.	3.3	1
24	Management of suspected and confirmed <scp>COVID</scp> â€19 (<scp>SARSâ€CoV</scp> â€2) vaccine hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3426-3434.	5.7	11
25	Prevalence of sensitization to molecular food allergens in Europe: A systematic review. Clinical and Translational Allergy, 2022, 12, .	3.2	2
26	Elicitors and phenotypes of adult patients with proven IgEâ€mediated food allergy and nonâ€immuneâ€mediated food hypersensitivity to food additives. Clinical and Experimental Allergy, 2022, 52, 1302-1310.	2.9	6
27	Serum autoantibody reactivity in bullous pemphigoid is associated with neuropsychiatric disorders and the use of antidiabetics and antipsychotics: a large, prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 2181-2189.	2.4	4
28	Phenotype and risk factors of venom-induced anaphylaxis: AÂcase-control study of the European Anaphylaxis Registry. Journal of Allergy and Clinical Immunology, 2021, 147, 653-662.e9.	2.9	40
29	Immunomodulation of highâ€dose vitamin D supplementation during allergenâ€specific immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 930-933.	5.7	12
30	Vitamin A controls the allergic response through T follicular helper cell as well as plasmablast differentiation. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1109-1122.	5.7	6
31	Tralokinumab for moderateâ€toâ€severe atopic dermatitis: results from two 52â€week, randomized, doubleâ€blind, multicentre, placeboâ€controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. British Journal of Dermatology, 2021, 184, 437-449.	1.5	289
32	Peanutâ€induced anaphylaxis in children and adolescents: Data from the European Anaphylaxis Registry. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1517-1527.	5.7	39
33	Reply. Journal of Allergy and Clinical Immunology, 2021, 147, 415.	2.9	O
34	Usefulness of an artificial neural network to assess anaphylaxis severity. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1244-1246.	5.7	2
35	9â€ <i>cis</i> Retinoic acid and 1.25â€dihydroxyvitamin D ₃ drive differentiation into lgA ⁺ secreting plasmablasts in human naÃ⁻ve B cells. European Journal of Immunology, 2021, 51, 125-137.	2.9	8
36	Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1041-1052.	5.7	38

#	Article	IF	CITATIONS
37	Diagnosing, managing and preventing anaphylaxis: Systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1493-1506.	5.7	40
38	A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial. Journal of Allergy and Clinical Immunology, 2021, 147, 1020-1030.e10.	2.9	50
39	Genetic variability of immuneâ€related lncRNAs: polymorphisms in <i>LINCâ€PINT</i> and <i>LY86â€AS1</i> are associated with pemphigus foliaceus susceptibility. Experimental Dermatology, 2021, 30, 831-840.	2.9	11
40	Induction of penicillin tolerance during pregnancy: Allergological opinion on the recommendation of the current AWMF Guidelines on Diagnosis and Treatment of Syphilis (AWMF Registry No. 059-002). Allergologie Select, 2021, 5, 67-71.	3.1	О
41	Anaphylaxis in middle-aged patients. Allergologie Select, 2021, 5, 133-139.	3.1	8
42	Update "Systemic treatment of atopic dermatitis―of the S2kâ€guideline on atopic dermatitis. JDDG - Journal of the German Society of Dermatology, 2021, 19, 151-168.	0.8	30
43	Practical recommendations for the allergological risk assessment of the COVID-19 vaccination – a harmonized statement of allergy centers in Germany. Allergologie Select, 2021, 5, 72-76.	3.1	22
44	COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI). Allergologie Select, 2021, 5, 251-259.	3.1	9
45	Update of the S2k guideline on the management of IgE-mediated food allergies. Allergologie Select, 2021, 5, 195-243.	3.1	42
46	Use of biologics in food allergy management. Allergologie Select, 2021, 5, 103-107.	3.1	5
47	COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) – A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergo. Allergologie Select, 2021, 5, 140-147.	3.1	28
48	Severe allergic reactions to the COVID-19 vaccine – statement and practical consequences. Allergologie Select, 2021, 5, 26-28.	3.1	33
49	Patch test results with caine mix <scp>III</scp> and its three constituents in consecutive patients of the <scp>IVDK</scp> . Contact Dermatitis, 2021, 84, 481-483.	1.4	4
50	COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organization Journal, 2021, 14, 100517.	3.5	121
51	Current developments in the treatment of peanut allergy. Allergo Journal International, 2021, 30, 56-63.	2.0	1
52	Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA. Allergo Journal International, 2021, 30, 51-55.	2.0	55
53	Atopic skin diathesis rather than atopic dermatitis is associated with specific contact allergies. JDDG - Journal of the German Society of Dermatology, 2021, 19, 231-240.	0.8	9
54	Component-resolved diagnosis in adult patients with food-dependent anaphylaxis. World Allergy Organization Journal, 2021, 14, 100530.	3.5	7

#	Article	IF	CITATIONS
55	Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1212-1223.e6.	3.8	31
56	A negative breakdown test in a fragrance mix lâ€positive patient does not rule out contact allergy to its fragrance constituents. Contact Dermatitis, 2021, 84, 407-418.	1.4	11
57	Wheat Anaphylaxis in Adults Differs from Reactions to Other Types of Food. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2844-2852.e5.	3.8	28
58	Practical handling of allergic reactions to COVID-19 vaccines. Allergo Journal International, 2021, 30, 79-95.	2.0	25
59	Risk of severe allergic reactions to COVIDâ€19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e362-e365.	2.4	24
60	Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis. Annals of Allergy, Asthma and Immunology, 2021, 126, 576-583.e4.	1.0	16
61	Targeted Use of Placebo Effects Decreases Experimental Itch in Atopic Dermatitis Patients: A Randomized Controlled Trial. Clinical Pharmacology and Therapeutics, 2021, 110, 486-497.	4.7	11
62	The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3546-3567.	3.8	152
63	When and how to evaluate for <i>immediate type</i> food allergy in children with atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3845-3848.	5.7	3
64	Anaphylaxis to vaccination and polyethylene glycol: a perspective from the European Anaphylaxis Registry. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e659-e662.	2.4	6
65	Safety of dupilumab in patients with atopic dermatitis: expert opinion. Expert Opinion on Drug Safety, 2021, 20, 997-1004.	2.4	12
66	ARIAâ€EAACI statement on severe allergic reactions to COVIDâ€19 vaccines – An EAACIâ€ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1624-1628.	5.7	66
67	Foodâ€induced anaphylaxis morbidity: Emergency department and hospitalization data support preventive strategies. Pediatric Allergy and Immunology, 2021, 32, 1730-1742.	2.6	6
68	S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1371-1395.	0.8	3
69	S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – PartÂ1: Classification, diagnosis, prevention, activity scores. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1236-1247.	0.8	8
70	Tralokinumab in atopic dermatitis. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1435-1442.	0.8	6
71	Messages for patients and relatives from the 2021 update of the guideline on acute therapy and management of anaphylaxis. Allergo Journal International, 2021, 30, 243-248.	2.0	9
72	Management of anaphylaxis due to COVIDâ€19 vaccines in the elderly. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2952-2964.	5.7	16

#	Article	IF	Citations
73	S2kâ€Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematodes – Teil 2: Therapie, Risikofaktoren und spezielle Fragestellungen. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1371-1395.	0.8	2
74	Genetic association and differential expression of HLA Complex Group IncRNAs in pemphigus. Journal of Autoimmunity, 2021, 123, 102705.	6.5	8
75	Guideline (S2k) on acute therapy and management of anaphylaxis: 2021 update. Allergo Journal International, 2021, 30, 1-25.	2.0	78
76	Identification and Purification of Novel Low-Molecular-Weight Lupine Allergens as Components for Personalized Diagnostics. Nutrients, 2021, 13, 409.	4.1	16
77	Precision medicine reaching out to the patients in allergology – a German-Japanese workshop report. Allergologie Select, 2021, 5, 162-179.	3.1	1
78	Guideline on management of suspected adverse reactions to ingested histamine - Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergology and Environmental Medicine (GPA), the Medical Association. Allergologie Select, 2021, 5, 305-314.	3.1	22
79	Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A doubleâ€blind Phase Ib study. Experimental Dermatology, 2021, 30, 1686-1692.	2.9	9
80	Thymic stromal lymphopoietin production induced by skin irritation results from concomitant activation of proteaseâ€activated receptor 2 and interleukin 1 pathways. British Journal of Dermatology, 2020, 182, 119-129.	1.5	12
81	Large Variability of Frequency and Type of Physical Therapy in Patients in the German Network for Systemic Sclerosis. Arthritis Care and Research, 2020, 72, 1041-1048.	3.4	3
82	The role of mobile health technologies in allergy care: An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 259-272.	5.7	95
83	Scleroderma Renal Crisis: Risk Factors for an Increasingly Rare Organ Complication. Journal of Rheumatology, 2020, 47, 241-248.	2.0	24
84	Conflicting verdicts on peanut oral immunotherapy from the Institute for Clinical and Economic Review and US Food and Drug Administration Advisory Committee: Where do we go from here?. Journal of Allergy and Clinical Immunology, 2020, 145, 1153-1156.	2.9	17
85	Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1263-1272.	2.4	41
86	Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 901-910.	5.7	10
87	Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, doubleâ€blind, vehicleâ€controlled phase <scp>II</scp> a study. British Journal of Dermatology, 2020, 182, 1103-1110.	1.5	69
88	Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis. JAMA Dermatology, 2020, 156, 131.	4.1	110
89	Recurrent eczema herpeticum – a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1074-1079.	2.4	32
90	Atopy patch testing with aeroallergens in a large clinical population of dermatitis patients in Germany and Switzerland, 2000â€2015: a retrospective multicentre study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2086-2095.	2.4	9

#	Article	IF	Citations
91	Modern therapies in atopic dermatitis: biologics and small molecule drugs. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1085-1092.	0.8	23
92	World Allergy Organization Anaphylaxis Guidance 2020. World Allergy Organization Journal, 2020, 13, 100472.	3.5	461
93	Therapy Changes During Pemphigus Management: A Retrospective Analysis. Frontiers in Medicine, 2020, 7, 581820.	2.6	3
94	Risk Factors and Characteristics of Biphasic Anaphylaxis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3388-3395.e6.	3.8	35
95	COVIDâ€19 and implications for dermatological and allergological diseases. JDDG - Journal of the German Society of Dermatology, 2020, 18, 815-824.	0.8	30
96	Is the concept of "peanut-free schools―useful in the routine management of peanut-allergic children at risk of anaphylaxis?. Allergo Journal International, 2020, 29, 169-173.	2.0	6
97	Healthcare provision for insect venom allergy patients during the COVID-19 pandemic. Allergo Journal International, 2020, 29, 257-261.	2.0	5
98	EAACI Task force Clinical epidemiology of anaphylaxis: experts' perspective on the use of adrenaline autoinjectors in Europe. Clinical and Translational Allergy, 2020, 10, 12.	3.2	12
99	PGE2 deficiency predisposes to anaphylaxis by causing mast cell hyperresponsiveness. Journal of Allergy and Clinical Immunology, 2020, 146, 1387-1396.e13.	2.9	31
100	S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update. JDDG - Journal of the German Society of Dermatology, 2020, 18, 516-526.	0.8	20
101	Features and Predictors of Biphasic Anaphylaxis: Data from the European Anaphylaxis Registry. Journal of Allergy and Clinical Immunology, 2020, 145, AB335.	2.9	1
102	Epinephrine delivery via EpiPen \hat{A}^{\otimes} Auto-Injector or manual syringe across participants with a wide range of skin-to-muscle distances. Clinical and Translational Allergy, 2020, 10, 21.	3.2	23
103	EAACI anaphylaxis guidelines: systematic review protocol. Clinical and Translational Allergy, 2020, 10, 14.	3.2	13
104	Dietary implications in acetylsalicylic acid intolerance. Allergo Journal International, 2020, 29, 93-96.	2.0	4
105	Good tolerability when switching from an aqueous ultraâ€rush Hymenoptera venom immunotherapy to a depot preparation. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1800-1802.	5.7	1
106	Implementation of dupilumab in routine care of atopic eczema: results from the German national registry <scp>TREAT</scp> germany. British Journal of Dermatology, 2020, 183, 382-384.	1.5	37
107	Older age onset of systemic sclerosis – accelerated disease progression in all disease subsets. Rheumatology, 2020, 59, 3380-3389.	1.9	14
108	TCRs with segment TRAV9â€⊋ or a CDR3 histidine are overrepresented among nickelâ€specific CD4+ T cells. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2574-2586.	5.7	16

#	Article	IF	Citations
109	Intravenous Immunoglobulins in a Series of 32 Rare and Recalcitrant Immune Dermatoses. Acta Dermato-Venereologica, 2020, 100, adv00298.	1.3	10
110	Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics. Allergologie Select, 2020, 4, 11-43.	3.1	26
111	Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA. Allergologie Select, 2020, 4, 44-52.	3.1	23
112	Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic. Allergologie Select, 2020, 4, 53-68.	3.1	38
113	Topical and Systemic Corticosteroids. , 2020, , 1433-1444.		6
114	AB0584â€DOES ANTI-ACID TREATMENT INFLUENCE DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS INTERSTITIAL LUNG DISEASE (SSC-ILD)? DATA FROM THE GERMAN SSC-NETWORK. Annals of the Rheumatic Diseases, 2020, 79, 1589-1589.	0.9	0
115	The frequency of specific contact allergies is reduced in patients with psoriasis. British Journal of Dermatology, 2019, 180, 315-320.	1.5	15
116	Oliveâ€Oilâ€Derived Polyphenols Effectively Attenuate Inflammatory Responses of Human Keratinocytes by Interfering with the NFâ€₽B Pathway. Molecular Nutrition and Food Research, 2019, 63, 1900019.	3.3	20
117	Thymic Stromal Lymphopoietin Interferes with the Apoptosis of Human Skin Mast Cells by a Dual Strategy Involving STAT5/Mcl-1 and JNK/Bcl-xL. Cells, 2019, 8, 829.	4.1	24
118	Repeated epinephrine doses: An analysis of the European Anaphylaxis Registry, 2007-2018. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2935-2937.	3.8	5
119	Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics. Allergo Journal International, 2019, 28, 121-151.	2.0	43
120	Drug-induced anaphylaxisâ€"elicitors, mechanisms and diagnosis. Allergo Journal International, 2019, 28, 327-329.	2.0	7
121	S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1. JDDG - Journal of the German Society of Dermatology, 2019, 17, 1076-1093.	0.8	81
122	ICER report for peanut OIT comes up short. Annals of Allergy, Asthma and Immunology, 2019, 123, 430-432.	1.0	15
123	Detection of KIT D816V mutation in patients with severe anaphylaxis and normal basal tryptaseâ€"first data from the Anaphylaxis Registry (NORA). Journal of Allergy and Clinical Immunology, 2019, 144, 1448-1450.e1.	2.9	13
124	Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases–11. Journal of Allergy and Clinical Immunology, 2019, 144, 627-633.	2.9	46
125	Contact urticaria: Frequency, elicitors and cofactors in three cohorts (Information Network of) Tj ETQq $1\ 1\ 0.784$	314 rgBT / 1.4	Overlock 10 26
126	Development of subcutaneous allergen immunotherapy (partÂ2): preventive aspects and innovations. Allergo Journal International, 2019, 28, 107-119.	2.0	13

#	Article	IF	CITATIONS
127	Anaphylaxis in Elderly Patientsâ€"Data From the European Anaphylaxis Registry. Frontiers in Immunology, 2019, 10, 750.	4.8	47
128	A caseâ€control analysis of skin contact allergy in children and adolescents. Pediatric Allergy and Immunology, 2019, 30, 632-637.	2.6	11
129	Randomized immunotherapy trial in dualâ€allergic patients using "active allergen placebo―as control. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1480-1489.	5.7	10
130	Evolution of subcutaneous allergen immunotherapy (partÂ1): from first developments to mechanism-driven therapy concepts. Allergo Journal International, 2019, 28, 78-95.	2.0	16
131	Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase <scp>III</scp> clinical trials. British Journal of Dermatology, 2019, 181, 196-197.	1.5	28
132	Severe Refractory Paraneoplastic Mucous Membrane Pemphigoid Successfully Treated With Rituximab. Frontiers in Medicine, 2019, 6, 8.	2.6	8
133	Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans. Cell, 2019, 176, 1340-1355.e15.	28.9	321
134	Editorial: Anaphylaxis – A Distinct Immunological Syndrome, but How Much Do We Really Understand?. Frontiers in Immunology, 2019, 10, 2943.	4.8	2
135	Time to revisit the definition and clinical criteria for anaphylaxis?. World Allergy Organization Journal, 2019, 12, 100066.	3.5	137
136	S3 Guidelines: Epicutaneous patch testing with contact allergens and drugs $\hat{a} \in \text{``Short version, Part 2.}$ JDDG - Journal of the German Society of Dermatology, 2019, 17, 1187-1207.	0.8	44
137	Refractory Anaphylaxis: Data From the European Anaphylaxis Registry. Frontiers in Immunology, 2019, 10, 2482.	4.8	41
138	Polymorphisms in the Mitochondrial Genome Are Associated With Bullous Pemphigoid in Germans. Frontiers in Immunology, 2019, 10, 2200.	4.8	4
139	Transcriptomic and lipidomic profiling of eicosanoid/docosanoid signalling in affected and nonâ€affected skin of human atopic dermatitis patients. Experimental Dermatology, 2019, 28, 177-189.	2.9	34
140	Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: A 2â€year doubleâ€blind, placeboâ€controlled, randomized trial plus 1â€year openâ€label extension. Clinical and Experimental Allergy, 2019, 49, 516-525.	2.9	18
141	Contact dermatitis and sensitization in professional musicians. Contact Dermatitis, 2019, 80, 273-278.	1.4	10
142	Proximity-Based Emergency Response Communities for Patients With Allergies Who Are at Risk of Anaphylaxis: Clustering Analysis and Scenario-Based Survey Study. JMIR MHealth and UHealth, 2019, 7, e13414.	3.7	11
143	Risk factors and treatment of refractory anaphylaxis - a review of case reports. Expert Review of Clinical Immunology, 2018, 14, 307-314.	3.0	22
144	Reply to Chirumbolo etÂal Pediatric Allergy and Immunology, 2018, 29, 461-462.	2.6	1

#	Article	IF	Citations
145	Epinephrine in Severe Allergic Reactions: The European Anaphylaxis Register. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1898-1906.e1.	3.8	83
146	Clinical reactivity of celery cultivars in allergic patients: Role of Api g 1. Clinical and Experimental Allergy, 2018, 48, 424-432.	2.9	8
147	Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32. Journal of Allergy and Clinical Immunology, 2018, 142, 497-509.e9.	2.9	84
148	Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1322-1330.	5.7	176
149	The urgent need for a harmonized severity scoring system for acute allergic reactions. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1792-1800.	5.7	79
150	Critical view of anaphylaxis epidemiology: open questions and new perspectives. Allergy, Asthma and Clinical Immunology, 2018, 14, 12.	2.0	59
151	Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season. Journal of Allergy and Clinical Immunology, 2018, 142, 678-680.e7.	2.9	21
152	9-cis retinoic acid modulates the type I allergic immune response. Journal of Allergy and Clinical Immunology, 2018, 141, 650-658.e5.	2.9	15
153	Meat allergy associated with galactosylâ€Î±â€(1,3)â€galactose (αâ€Gal)â€"Closing diagnostic gaps by antiâ€Î±â immune profiling. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 93-105.	iۂal IgE	40
154	EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 765-798.	5.7	473
155	Persistent cow′s milk anaphylaxis from early childhood monitored by IgE and <scp>BAT</scp> to cow′s and human milk under therapy. Pediatric Allergy and Immunology, 2018, 29, 210-214.	2.6	10
156	Adrenaline in the Acute Treatment of Anaphylaxis. Deutsches Ärzteblatt International, 2018, 115, 528-534.	0.9	35
157	Wissensstand zur Anaphylaxie und Umgang mit Adrenalinautoinjektoren in Apotheken. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1315-1322.	0.8	0
158	Pemphigus Foliaceusâ€"Repeated Treatment With Rituximab 7 Years After Initial Response: A Case Report. Frontiers in Medicine, 2018, 5, 315.	2.6	2
159	Olaparib Desensitization in a Patient with Recurrent Peritoneal Cancer. New England Journal of Medicine, 2018, 379, 2176-2177.	27.0	15
160	Foodâ€induced fatal anaphylaxis: From epidemiological data to general prevention strategies. Clinical and Experimental Allergy, 2018, 48, 1584-1593.	2.9	120
161	Level of knowledge among pharmacists regarding anaphylaxis and the use of epinephrine autoinjectors. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1315-1321.	0.8	2
162	The p.Arg435His Variation of IgG3 With High Affinity to FcRn Is Associated With Susceptibility for Pemphigus Vulgaris—Analysis of Four Different Ethnic Cohorts. Frontiers in Immunology, 2018, 9, 1788.	4.8	17

#	Article	IF	CITATIONS
163	Non-celiac gluten/wheat sensitivity (NCGS)—aÂcurrently undefined disorder without validated diagnostic criteria and of unknown prevalence. Allergo Journal International, 2018, 27, 147-151.	2.0	33
164	Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1812-1822.	5.7	24
165	Propionibacterium acnes Abundance Correlates Inversely with Staphylococcus aureus: Data from Atopic Dermatitis Skin Microbiome. Acta Dermato-Venereologica, 2018, 98, 490-495.	1.3	54
166	Topical and Systemic Corticosteroids. , 2018, , 1-12.		0
167	Immunomodulation by vitamin D. Allergologie Select, 2018, 2, 62-66.	3.1	3
168	Precision medicine in allergic disease—food allergy, drug allergy, and anaphylaxis— <scp>PRACTALL</scp> document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1006-1021.	5.7	143
169	Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial. Journal of Allergy and Clinical Immunology, 2017, 140, 845-853.e3.	2.9	87
170	The Impact on Allergy-Related Cells of a Birch Pollen Allergoid, with and without Monophosphoryl Lipid A, in Comparison with the Native Equivalent. International Archives of Allergy and Immunology, 2017, 172, 20-26.	2.1	10
171	Dupilumab in the treatment of moderate-to-severe atopic dermatitis. Expert Review of Clinical Immunology, 2017, 13, 301-310.	3.0	39
172	An efficient method for gene knockâ€down by <scp>RNA</scp> interference in human skin mast cells. Experimental Dermatology, 2017, 26, 1136-1139.	2.9	21
173	Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and metaâ€analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1597-1631.	5.7	233
174	Current Standards and Improvements in the Use of SLIT Tablets for Allergen Immunotherapy. Current Treatment Options in Allergy, 2017, 4, 286-289.	2.2	1
175	Serum levels of $9\hat{l}_{\pm},11\hat{l}^2$ -PGF2 and apolipoprotein A1 achieve high predictive power as biomarkers of anaphylaxis. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1801-1805.	5.7	12
176	German guideline for the management of adverse reactions to ingested histamine. Allergo Journal International, 2017, 26, 72-79.	2.0	69
177	<scp>BASALIT</scp> trial: doubleâ€blind placeboâ€controlled allergen immunotherapy with <scp>rB</scp> et v 1â€ <scp>FV</scp> in birchâ€related soya allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1243-1253.	5.7	40
178	Apoptotic resistance of human skin mast cells is mediated by McI-1. Cell Death Discovery, 2017, 3, 17048.	4.7	16
179	European dermatology forum S1â€guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1581-1594.	2.4	79
180	European Dermatology Forum S1â€guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1401-1424.	2.4	148

#	Article	IF	Citations
181	Doseâ€response relationship of a new Timothy grass pollen allergoid in comparison with a 6â€grass pollen allergoid. Clinical and Experimental Allergy, 2017, 47, 1445-1455.	2.9	16
182	Genomewide association study identifies <i>GALC</i> as susceptibility gene for mucous membrane pemphigoid. Experimental Dermatology, 2017, 26, 1214-1220.	2.9	16
183	New trends in anaphylaxis. Allergo Journal International, 2017, 26, 295-300.	2.0	15
184	Endogenous Calcitriol Synthesis Controls the Humoral IgE Response in Mice. Journal of Immunology, 2017, 199, 3952-3958.	0.8	10
185	Quality indicators for the acute and long-term management of anaphylaxis: a systematic review. Clinical and Translational Allergy, 2017, 7, 15.	3.2	7
186	In-flight allergic emergencies. World Allergy Organization Journal, 2017, 10, 15.	3.5	24
187	Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. Clinical and Translational Allergy, 2017, 7, 24.	3.2	49
188	Pharmacokinetic Evaluation of a Single Intramuscular High Dose versus an Oral Long-Term Supplementation of Cholecalciferol. PLoS ONE, 2017, 12, e0169620.	2.5	16
189	Ethylene oxide as an occupational contact allergen – an underestimated problem?. Allergologie Select, 2017, 1, 9-13.	3.1	4
190	Food-induced anaphylaxis and cofactors $\hat{a} \in \hat{a}$ data from the anaphylaxis registry. Allergologie Select, 2017, 1, 21-27.	3.1	22
191	Elicitors of severe allergic reactions – reports from allergists and emergency doctors. Allergologie Select, 2017, 1, 14-20.	3.1	1
192	A Promoter Polymorphism of the Vitamin D Metabolism Gene Cyp24a1 is Associated with Severe Atopic Dermatitis in Adults. Acta Dermato-Venereologica, 2016, 96, 169-172.	1.3	19
193	Bortezomib treatment diminishes hazelnutâ€induced intestinal anaphylaxis in mice. European Journal of Immunology, 2016, 46, 1727-1736.	2.9	8
194	Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. Clinical and Translational Allergy, 2016, 6, 41.	3.2	24
195	A variant of the <i>CXCL11 </i> gene may influence susceptibility to contact allergy, particularly in polysensitized patients. Contact Dermatitis, 2016, 75, 303-307.	1.4	19
196	Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. New England Journal of Medicine, 2016, 375, 2335-2348.	27.0	1,467
197	Can we identify patients at risk of lifeâ€threatening allergic reactions to food?. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1241-1255.	5.7	176
198	German guidelines for the diagnosis and therapy of localized scleroderma. JDDG - Journal of the German Society of Dermatology, 2016, 14, 199-216.	0.8	97

#	Article	IF	Citations
199	S2k guideline on diagnosis and treatment of atopic dermatitis $\hat{a} \in \text{``short version. JDDG - Journal of the}$ German Society of Dermatology, 2016, 14, 92-105.	0.8	49
200	Impact of systemic alitretinoin treatment on skin barrier gene and protein expression in patients with chronic hand eczema. British Journal of Dermatology, 2016, 175, 1243-1250.	1.5	20
201	Standardization of double blind placebo controlled food challenge with soy within a multicentre trial. Clinical and Translational Allergy, 2016, 6, 39.	3.2	20
202	Regulatory T Cell Specificity Directs Tolerance versus Allergy against Aeroantigens in Humans. Cell, 2016, 167, 1067-1078.e16.	28.9	253
203	Polyethylene glycol as a cause of anaphylaxis. Allergy, Asthma and Clinical Immunology, 2016, 12, 67.	2.0	65
204	Exploratory analysis of CD63 and CD203c expression in basophils from hazelnut sensitized and allergic individuals. Clinical and Translational Allergy, 2016, 6, 45.	3.2	15
205	Supportive care of patients with anaphylaxis â€" options and shortcomings: an assessment on behalf of the working group on anaphylaxis training and education (AGATE), Germany. Allergo Journal International, 2016, 25, 160-168.	2.0	7
206	Cost utility analysis of the SQÂ $^{\odot}$ HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting. Clinical and Translational Allergy, 2016, 6, 35.	3.2	7
207	Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase Ilb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). Journal of the American Academy of Dermatology, 2016, 75, 506-515.	1.2	132
208	S2k guideline on diagnosis and treatment of atopic dermatitis $\hat{a} \in$ " short version. Allergo Journal International, 2016, 25, 82-95.	2.0	60
209	Guidelines on dermatomyositis – excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. JDDG - Journal of the German Society of Dermatology, 2016, 14, 321-338.	0.8	43
210	Efficacy of 2Âmonths of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study. Journal of Allergy and Clinical Immunology, 2016, 138, 162-168.	2.9	61
211	New opportunities for allergen immunotherapy using synthetic peptide immuno-regulatory epitopes (SPIREs). Expert Review of Clinical Immunology, 2016, 12, 1123-1135.	3.0	20
212	Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review. Clinical and Translational Allergy, 2016, 6, 12.	3.2	14
213	The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase†antibodies. British Journal of Dermatology, 2016, 174, 1384-1387.	1.5	14
214	S2kâ€Leitlinie Neurodermitis [atopisches Ekzem; atopische Dermatitis] – Kurzversion. JDDG - Journal of the German Society of Dermatology, 2016, 14, 92-106.	0.8	65
215	Anaphylaxis in children and adolescents: The European Anaphylaxis Registry. Journal of Allergy and Clinical Immunology, 2016, 137, 1128-1137.e1.	2.9	438
216	Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients. Journal of Rheumatology, 2016, 43, 66-74.	2.0	42

#	Article	IF	Citations
217	Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet, The, 2016, 387, 40-52.	13.7	471
218	Serum levels of $9\hat{l}_{\pm}$, $11\hat{l}^2$ -PGF 2 and cysteinyl leukotrienes are useful biomarkers of anaphylaxis. Journal of Allergy and Clinical Immunology, 2016, 137, 312-314.e7.	2.9	32
219	Nahrungsmittelanaphylaxie. Daten aus dem deutschsprachigen Anaphylaxie- Register 2006 – 2015. Allergologie, 2016, 39, 390-395.	0.1	1
220	Dem TÄter auf der Spur: Indikation und praktische Umsetzung von Nahrungsmittelprovokationen im Erwachsenenalter. Allergologie, 2016, 39, 523-532.	0.1	7
221	B-Lymphozyten und der Antikörperklassenwechsel zu lgE. , 2016, , 95-103.		0
222	Digital ulcers score: a scoring system to assess digital ulcers in patients suffering from systemic sclerosis. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 142-147.	0.8	4
223	<scp>EAACI</scp> position paper for practical patch testing in allergic contact dermatitis in children. Pediatric Allergy and Immunology, 2015, 26, 598-606.	2.6	62
224	Intake of cardiovascular drugs promote severity of anaphylaxis. Clinical and Translational Allergy, 2015, 5, P4.	3.2	0
225	Prolonged efficacy of the 300IR 5â€grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clinical and Translational Allergy, 2015, 5, 12.	3.2	92
226	Effects of a structured educational intervention on knowledge and emergency management in patients at risk for anaphylaxis. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 227-235.	5.7	91
227	SAT0440â€New Data on Renal Crisis and Predictive Markers from More Than 3000 Patients. Annals of the Rheumatic Diseases, 2015, 74, 819.2-819.	0.9	1
228	S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid. JDDG - Journal of the German Society of Dermatology, 2015, 13, 833-844.	0.8	76
229	S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid. JDDG - Journal of the German Society of Dermatology, 2015, 13, 713-727.	0.8	69
230	S2kâ€Leitlinie zur Diagnostik des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoids. JDDG - Journal of the German Society of Dermatology, 2015, 13, 713-727.	0.8	54
231	Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study. Clinical and Experimental Gastroenterology, 2015, 8, 205.	2.3	15
232	Low-dose Anti-thymocyte Globulin Inhibits Human B-cell Differentiation into Antibody-Secreting Cells. Acta Dermato-Venereologica, 2015, 95, 676-680.	1.3	6
233	Guideline for the diagnosis of drug hypersensitivity reactions. Allergo Journal International, 2015, 24, 94-105.	2.0	139
234	Rituximab preserves vision in ocular mucous membrane pemphigoid. Expert Opinion on Biological Therapy, 2015, 15, 927-933.	3.1	28

#	Article	IF	Citations
235	Position paper of the <scp>EAACI</scp> : food allergy due to immunological crossâ€reactions with common inhalant allergens. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1079-1090.	5.7	164
236	Guidelines on the management of IgE-mediated food allergies. Allergo Journal International, 2015, 24, 256-293.	2.0	129
237	Ramipril and metoprolol intake aggravate human and murine anaphylaxis: Evidence for direct mast cell priming. Journal of Allergy and Clinical Immunology, 2015, 135, 491-499.	2.9	98
238	Rituximab in patients with recalcitrant autoimmune blistering diseases: experience in a cohort of 22 patients. British Journal of Dermatology, 2015, 172, 829-831.	1.5	12
239	Characterization of oral immune cells in birch pollen-allergic patients: impact of the oral allergy syndrome and sublingual allergen immunotherapy on antigen-presenting cells. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 408-419.	5.7	16
240	Malassezia sppspecific Immunoglobulin E Level is a Marker for Severity of Atopic Dermatitis in Adults. Acta Dermato-Venereologica, 2015, 95, 191-196.	1.3	61
241	Retinoic acid potentiates inflammatory cytokines in human mast cells: Identification of mast cells as prominent constituents of the skin retinoid network. Molecular and Cellular Endocrinology, 2015, 406, 49-59.	3.2	25
242	Impact of sex on anaphylaxis severity—data from the Anaphylaxis Registry. Journal of Allergy and Clinical Immunology, 2015, 136, 1425-1426.	2.9	24
243	2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organization Journal, 2015, 8, 32.	3.5	422
244	SPIREs: a new horizon for allergic disease treatment?. Expert Review of Clinical Immunology, 2015, 11, 1173-1175.	3.0	7
245	Clinical Efficacy and Tolerability of a Novel Selective Corticosteroid in Atopic Dermatitis - Two Randomised Controlled Trials. Skin Pharmacology and Physiology, 2015, 28, 159-166.	2.5	10
246	Thymic stromal lymphopoietin induction by skin irritation is independent of tumour necrosis factor-α, but supported by interleukin-1. British Journal of Dermatology, 2015, 172, 951-960.	1.5	22
247	Allergen and allergy risk assessment, allergen management, and gaps in the European Food Information Regulation (FIR). Allergo Journal International, 2015, 24, 180-184.	2.0	28
248	Data from the anaphylaxis registry of the German-speaking countries. Revue Francaise D'allergologie, 2015, 55, 452-455.	0.2	4
249	Contact sensitization in patients with suspected cosmetic intolerance: results of the <scp>IVDK</scp> 2006–2011. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1071-1081.	2.4	44
250	Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 730-737.	0.9	82
251	In Reply. Deutsches Ärzteblatt International, 2015, 112, 59.	0.9	0
252	Triggers and Treatment of Anaphylaxis. Deutsches Ärzteblatt International, 2014, 111, 367-75.	0.9	162

#	Article	IF	CITATIONS
253	S3-Guideline on allergy prevention: 2014 update. Allergo Journal International, 2014, 23, 186-199.	2.0	58
254	Oral vitamin <scp>D</scp> increases the frequencies of <scp>CD</scp> 38 ⁺ human <scp>B</scp> cells and ameliorates <scp>IL</scp> â€17â€producing <scp>T</scp> cells. Experimental Dermatology, 2014, 23, 107-112.	2.9	50
255	Anaphylaxis treatment: current barriers to adrenaline auto-injector use. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 983-991.	5.7	71
256	Management of anaphylaxis: a systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 168-175.	5.7	109
257	First European data from the network of severe allergic reactions (<scp>NORA</scp>). Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1397-1404.	5.7	247
258	Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases. Allergo Journal International, 2014, 23, 282-319.	2.0	338
259	Tolerability and Clinical Outcome of Coseasonal Treatment with <i>Escherichia coli</i> Strain Nissle 1917 in Grass Pollen-Allergic Subjects. International Archives of Allergy and Immunology, 2014, 163, 29-35.	2.1	19
260	Immunomodulation in Patients with Chronic Hand Eczema Treated with Oral Alitretinoin. International Archives of Allergy and Immunology, 2014, 165, 18-26.	2.1	29
261	Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a doubleâ€blind, placeboâ€controlled study. Clinical and Translational Allergy, 2014, 4, 7.	3.2	39
262	Food allergies resulting from immunological cross-reactivity with inhalant allergens. Allergo Journal International, 2014, 23, 1-16.	2.0	54
263	Autocrine ILâ€10 promotes human Bâ€cell differentiation into IgMâ€or IgGâ€secreting plasmablasts. European Journal of Immunology, 2014, 44, 1615-1621.	2.9	98
264	The allergic emergency – management of severe allergic reactions. JDDG - Journal of the German Society of Dermatology, 2014, 12, 379-388.	0.8	10
265	Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the <scp>EUSCLE</scp> database. British Journal of Dermatology, 2014, 171, 571-579.	1.5	68
266	25-Hydroxvitamin D3 Promotes the Long-Term Effect of Specific Immunotherapy in a Murine Allergy Model. Journal of Immunology, 2014, 193, 1017-1023.	0.8	44
267	Commentary on   Dynamic Analysis of Histamine-Mediated Attenuation of Acetylcholine-Induced Sweating via GSK3 β Activation''. Journal of Investigative Dermatology, 2014, 134, 302-303.	0.7	0
268	Allergic contact dermatitis beyond IL- $1\hat{l}^2$ role of additional family members. Experimental Dermatology, 2014, 23, 151-152.	2.9	10
269	Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1026-1045.	5.7	809
270	International consensus on (ICON) anaphylaxis. World Allergy Organization Journal, 2014, 7, 9.	3.5	360

#	Article	IF	Citations
271	Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Research and Therapy, 2014, 16, R29.	3.5	125
272	Guideline for acute therapy and management of anaphylaxis. Allergo Journal International, 2014, 23, 96-112.	2.0	210
273	Guidelines on the use of extracorporeal photopheresis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1-37.	2.4	212
274	Impaired T cell activation and cytokine production by calcitriol-primed human B cells. Clinical and Experimental Immunology, 2014, 178, 364-372.	2.6	48
275	Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2014, 133, 1608-1614.e6.	2.9	177
276	EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1008-1025.	5.7	979
277	FRIO488â€Analysis of REAL Life Vasoactive Therapy in over 3000 Patients with Systemic Sclerosis (SSC) Reveals Considerable Undertreatment and Significant Changes of Treatment Practice since 2004. Annals of the Rheumatic Diseases, 2014, 73, 564.1-564.	0.9	0
278	Der allergologische Notfall – Management der Anaphylaxie. JDDG - Journal of the German Society of Dermatology, 2014, 12, 379-389.	0.8	11
279	How to Psychologically Minimize Scratching Impulses. Zeitschrift Fur Psychologie / Journal of Psychology, 2014, 222, 140-147.	1.0	9
280	Risikofaktoren f $\tilde{A}\frac{1}{4}$ r schwere Reaktionen und Anaphylaxie. Allergologie, 2014, 37, 251-257.	0.1	1
281	Impact of comorbidities on the treatment of atopic dermatitis in clinical practice. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 726-731.	0.6	6
282	The acute and longâ€term management of anaphylaxis: protocol for a systematic review. Clinical and Translational Allergy, 2013, 3, 14.	3.2	13
283	The epidemiology of anaphylaxis in Europe: protocol for a systematic review. Clinical and Translational Allergy, 2013, 3, 9.	3.2	15
284	Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis. Expert Opinion on Investigational Drugs, 2013, 22, 1347-1357.	4.1	26
285	The epidemiology of anaphylaxis in Europe: a systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1353-1361.	5.7	306
286	The placebo effect in allergenâ€specific immunotherapy trials. Clinical and Translational Allergy, 2013, 3, 42.	3.2	51
287	Elicitors and coâ€factors in foodâ€induced anaphylaxis in adults. Clinical and Translational Allergy, 2013, 3, 38.	3.2	45
288	Prevalence and treatment profile of patients with grass pollen and house dust mite allergy. JDDG - Journal of the German Society of Dermatology, 2013, 11, 653-661.	0.8	11

#	Article	IF	Citations
289	Opposing effects on immune function and skin barrier regulation by the proteasome inhibitor bortezomib in an allergenâ€induced eczema model. Experimental Dermatology, 2013, 22, 742-747.	2.9	11
290	A nematode immunomodulator suppresses grass pollen-specific allergic responses by controlling excessive Th2 inflammation. International Journal for Parasitology, 2013, 43, 201-210.	3.1	56
291	Evaluation of commercial skin prick test solutions for selected occupational allergens. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 651-658.	5.7	67
292	Causes and risk factors for anaphylaxis. JDDG - Journal of the German Society of Dermatology, 2013, 11, 44-50.	0.8	23
293	Auslöser und Risikofaktoren der Anaphylaxie. JDDG - Journal of the German Society of Dermatology, 2013, 11, 44-51.	0.8	24
294	Association of vitamin D receptor gene polymorphisms with severe atopic dermatitis in adults. British Journal of Dermatology, 2013, 168, 855-858.	1.5	73
295	World Allergy Organization Anaphylaxis Guidelines: 2013 Update of the Evidence Base. International Archives of Allergy and Immunology, 2013, 162, 193-204.	2.1	241
296	Cabbage Allergy: A Rare Cause of Food-induced Anaphylaxis. Acta Dermato-Venereologica, 2013, 93, 485-486.	1.3	10
297	Dietary polyunsaturated fatty acids and nonâ€digestible oligosaccharides reduce dermatitis in mice. Pediatric Allergy and Immunology, 2013, 24, 361-367.	2.6	18
298	Postâ€treatment efficacy of discontinuous treatment with 300IR 5â€grass pollen sublingual tablet in adults with grass pollenâ€induced allergic rhinoconjunctivitis. Clinical and Experimental Allergy, 2013, 43, 568-577.	2.9	78
299	Allergic contact dermatitis in children: which factors are relevant? (review of the literature). Pediatric Allergy and Immunology, 2013, 24, 321-329.	2.6	58
300	Identification of putative new tomato allergens and differential interaction with IgEs of tomato allergic subjects. Clinical and Experimental Allergy, 2013, 43, 1419-1427.	2.9	15
301	SAT0209â€The Risk for Initial Digital Ulcer Involvement in SSC Patients Decreases with Disease Duration Since the Beginning of Raynaud Phenomenon. Annals of the Rheumatic Diseases, 2013, 72, A651.2-A651.	0.9	0
302	Häfigkeit und Versorgungsprofil von Patienten mit Gräerpollen- und Hausstaubmilbenallergie. JDDG - Journal of the German Society of Dermatology, 2013, 11, 653-661.	0.8	9
303	Influence of bosentan on fingertip rewarming in patients with systemic sclerosis. JDDG - Journal of the German Society of Dermatology, 2013, 11, 356-359.	0.8	0
304	Pepino mosaic virus Infection of Tomato Affects Allergen Expression, but Not the Allergenic Potential of Fruits. PLoS ONE, 2013, 8, e65116.	2.5	18
305	Seltene Nahrungsmittelallergene – Daten aus dem Anaphylaxie-Register. Allergologie, 2013, 36, 204-209.	0.1	2
306	Nahrungsmittelallergie. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2013, , 460-472.	0.0	0

#	Article	IF	Citations
307	2012 Update. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 389-399.	2.3	236
308	Vitamin D Receptor Activation Improves Allergen-Triggered Eczema in Mice. Journal of Investigative Dermatology, 2012, 132, 330-336.	0.7	40
309	Implementation of Anaphylaxis Management Guidelines: A Register-Based Study. PLoS ONE, 2012, 7, e35778.	2.5	54
310	Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clinical and Translational Allergy, 2012, 2, 21.	3.2	127
311	Anaphylaxis in an emergency setting – elicitors, therapy and incidence of severe allergic reactions. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1451-1456.	5.7	94
312	Symptom profile and risk factors of anaphylaxis in Central Europe. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 691-698.	5.7	149
313	Topical therapy of hand eczema – analysis of the prescription profile from dermatologists in private practice. JDDG - Journal of the German Society of Dermatology, 2012, 10, 180-184.	0.8	8
314	Topische Therapie des Handekzems - Analyse des Verordnungsprofils in dermatologischen Praxen. JDDG - Journal of the German Society of Dermatology, 2012, 10, 180-185.	0.8	10
315	Atopic dermatitis and allergic rhinitis – do coâ€effects in therapy exist?. JDDG - Journal of the German Society of Dermatology, 2012, 10, 221-239.	0.8	3
316	Atopische Dermatitis und allergische Rhinitis - gibt es Co-Effekte in der Therapie?. JDDG - Journal of the German Society of Dermatology, 2012, 10, 221-236.	0.8	0
317	Human Langerhans Cells Control Th Cells via Programmed Death-Ligand 1 in Response to Bacterial Stimuli and Nickel-Induced Contact Allergy. PLoS ONE, 2012, 7, e46776.	2.5	16
318	Vorgehen bei Verdacht auf UnvertrÄ g lichkeit gegenļber oral aufgenommenem Histamin. Allergologie, 2012, 35, 335-342.	0.1	1
319	Topical and Systemic Corticosteroids. , 2012, , 1035-1043.		0
320	The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: AÂGlobal Allergy and Asthma European Network (GA2LEN) article. Journal of Allergy and Clinical Immunology, 2011, 127, 49-56.e11.	2.9	42
321	Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. Journal of Allergy and Clinical Immunology, 2011, 127, 89-97.e14.	2.9	159
322	Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patientsÂwith grass pollen–induced rhinoconjunctivitis. Journal of Allergy and Clinical Immunology, 2011, 128, 559-566.	2.9	155
323	Isolation of Human B Cell Populations. Current Protocols in Immunology, 2011, 94, Unit7.5.	3.6	4
324	Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features. Arthritis Research and Therapy, 2011, 13, R172.	3.5	133

#	Article	IF	Citations
325	1,25-dihydroxyvitamin D3 impairs NF-l̂ºB activation in human naÃ⁻ve B cells. Biochemical and Biophysical Research Communications, 2011, 407, 699-702.	2.1	69
326	Measurement of Proliferative Responses of Cultured Lymphocytes. Current Protocols in Immunology, 2011, 94, Unit7.10.	3.6	39
327	Targeting the vitamin D receptor inhibits the B cellâ€dependent allergic immune response. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 540-548.	5.7	104
328	MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 596-604.	5.7	146
329	Dietary docosahexaenoic acid in combination with arachidonic acid ameliorates allergenâ€induced dermatitis in mice. Pediatric Allergy and Immunology, 2011, 22, 497-504.	2.6	16
330	Provoking allergens and treatment of anaphylaxis in children and adolescents – data from the anaphylaxis registry of Germanâ€speaking countries. Pediatric Allergy and Immunology, 2011, 22, 568-574.	2.6	137
331	Allergenic activity of different tomato cultivars in tomato allergic subjects. Clinical and Experimental Allergy, 2011, 41, 1643-1652.	2.9	26
332	Late reactions to patch test preparations with reduced concentrations of p-phenylenediamine: a multicentre investigation of the German Contact Dermatitis Research Group. Contact Dermatitis, 2011, 64, 196-202.	1.4	22
333	Decreased retinoid concentration and retinoid signalling pathways in human atopic dermatitis. Experimental Dermatology, 2011, 20, 326-330.	2.9	46
334	Oral administration of Escherichia coli Nissle 1917 prevents allergen-induced dermatitis in mice. Experimental Dermatology, 2011, 20, 805-809.	2.9	38
335	10 years quality assurance of the dermatologist's procedure. ABD review board part II: 2003–2009. JDDG - Journal of the German Society of Dermatology, 2011, 9, 42-46.	0.8	12
336	Efficient tetanus toxoid immunization on vitamin D supplementation. European Journal of Clinical Nutrition, 2011, 65, 329-334.	2.9	31
337	Impact of arbuscular mycorrhizal fungi on the allergenic potential of tomato. Mycorrhiza, 2011, 21, 341-349.	2.8	17
338	Q&A: Food additive intolerance. BMC Medicine, 2011, 9, 115.	5 . 5	2
339	Tomato allergy: impact of genotype and environmental factors on the biological response. Journal of the Science of Food and Agriculture, 2011, 91, 2234-2240.	3.5	13
340	Inhibition of IgE production by docosahexaenoic acid is mediated by direct interference with STAT6 and NF $\hat{\mathbb{P}}$ B pathway in human B cells. Journal of Nutritional Biochemistry, 2011, 22, 269-275.	4.2	33
341	Auslöserprofile anaphylaktischer Reaktionen – vom niedergelassenen Allergologen bis zum Notfalleinsatz. Allergologie, 2011, 34, 60-67.	0.1	3
342	Versorgungsprofil von Patienten mit schweren allergischen Reaktionen. Allergologie, 2011, 34, 285-293.	0.1	1

#	Article	IF	Citations
343	Allergy for a Lifetime?. Allergology International, 2010, 59, 1-8.	3.3	35
344	Whole blood flow cytometric measurement of NFATc1 and ILâ€2 expression to analyze cyclosporine Aâ€mediated effects in T cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 607-613.	1.5	23
345	Identification of IgE Binding to Api g 1â€Derived Peptides. ChemBioChem, 2010, 11, 2283-2293.	2.6	9
346	Occupational contact dermatitis from ninhydrin in a police officer. Contact Dermatitis, 2010, 62, 59-60.	1.4	1
347	Increased sensitivity of patch testing by standardized tape stripping beforehand: a multicentre diagnostic accuracy study. Contact Dermatitis, 2010, 62, 294-302.	1.4	43
348	Quantitative repeated open application testing with a rinseâ€off product in methyldibromo glutaronitrileâ€sensitive patients: results of the IVDK. Contact Dermatitis, 2010, 62, 330-337.	1.4	11
349	Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema. British Journal of Dermatology, 2010, 162, 420-426.	1.5	88
350	Vitamin D deficiency in patients with cutaneous lupus erythematosus is prevalent throughout the year. British Journal of Dermatology, 2010, 163, 863-865.	1.5	35
351	Tamoxifen counteracts the allergic immune response and improves allergenâ€induced dermatitis in mice. Clinical and Experimental Allergy, 2010, 40, 1256-1265.	2.9	22
352	Epidemiology of urticaria: a representative cross-sectional population survey. Clinical and Experimental Dermatology, 2010, 35, 869-873.	1.3	264
353	Towards a European registry of severe allergic reactions: current status of national registries and future needs. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 671-680.	5.7	40
354	Longâ€term reduction in local inflammation by a lipid raft molecule in atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1158-1165.	5.7	21
355	Antihistamineâ€resistant urticaria factitia successfully treated with antiâ€mmunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1494-1495.	5.7	46
356	The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicleâ€controlled study. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1594-1599.	5.7	15
357	GA ² LEN/EAACI pocket guide for allergenâ€specific immunotherapy for allergic rhinitis and asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1525-1530.	5.7	185
358	Epidemiology of Anaphylaxis. Chemical Immunology and Allergy, 2010, 95, 12-21.	1.7	32
359	Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database. Journal of Rheumatology, 2010, 37, 1488-1501.	2.0	161
360	Safety of a rush immunotherapy build-up schedule with depigmented polymerized allergen extracts. Allergy and Asthma Proceedings, 2010, 31, 31-38.	2.2	21

#	Article	IF	CITATIONS
361	Interleukin-17A Promotes IgE Production in Human B Cells. Journal of Investigative Dermatology, 2010, 130, 2621-2628.	0.7	91
362	Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Annals of the Rheumatic Diseases, 2010, 69, 1475-1478.	0.9	101
363	Low-dose, but not high-dose, cyclosporin AÂpromotes regulatory T-cell induction, expansion, or both. Journal of Allergy and Clinical Immunology, 2010, 126, 183-184.	2.9	25
364	Vitamin D receptor binds to the $\hat{l}\mu$ germline gene promoter and exhibits transrepressive activity. Journal of Allergy and Clinical Immunology, 2010, 126, 1016-1023.e4.	2.9	40
365	Correction Required. Deutsches Ärzteblatt International, 2010, 107, 39; author reply 40-1.	0.9	0
366	Liver X Receptors Control IgE Expression in B Cells. Journal of Immunology, 2009, 182, 5276-5282.	0.8	52
367	Exogenous Histamine Aggravates Eczema in a Subgroup of Patients with Atopic Dermatitis. Acta Dermato-Venereologica, 2009, 89, 52-56.	1.3	22
368	Guideline on the Management of Hand Eczema ICDâ€10 Code: L20. L23. L24. L25. L30. JDDG - Journal of the German Society of Dermatology, 2009, 7, S1.	0.8	24
369	Management von Handekzemen Leitlinie ICDâ€10â€Ziffer: L20. L23. L24. L25. L30 JDDG - Journal of the German Society of Dermatology, 2009, 7, S1.	0.8	39
370	AWMFâ€Leitlinie Nr. 013/066 Diagnostik und Therapie der zirkumskripten Sklerodermie. JDDG - Journal of the German Society of Dermatology, 2009, 7, S1.	0.8	126
371	Isolation and phenotypic characterization of mucosal nasal lymphocytes by direct ex vivo analysis. European Archives of Oto-Rhino-Laryngology, 2009, 266, 677-683.	1.6	2
372	Advances in the management of UVR-associated skin cancers: autoimmune diseases and UV protection. British Journal of Dermatology, 2009, 161, 96-98.	1.5	2
373	Impact of native, heatâ€processed and encapsulated hazelnuts on the allergic response in hazelnutâ€allergic patients. Clinical and Experimental Allergy, 2009, 39, 159-166.	2.9	55
374	Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment. Clinical and Experimental Allergy, 2009, 39, 394-400.	2.9	29
375	Risk factors of adverse reactions to food in German adults. Clinical and Experimental Allergy, 2009, 39, 1036-1044.	2.9	35
376	Allergen extractâ€induced interleukinâ€10 in human memory B cells inhibits immunoglobulin E production. Clinical and Experimental Allergy, 2009, 39, 671-678.	2.9	18
377	Gastrointestinal nematode infection interferes with experimental allergic airway inflammation but not atopic dermatitis. Clinical and Experimental Allergy, 2009, 39, 1585-1596.	2.9	53
378	Occupational airborne contact allergy to tetrazepam in a geriatric nurse. JDDG - Journal of the German Society of Dermatology, 2009, 7, 896-898.	0.8	5

#	Article	IF	CITATIONS
379	Quantitative patch and repeated open application testing in hydroxyisohexyl 3â€cyclohexene carboxaldehyde sensitiveâ€patients. Contact Dermatitis, 2009, 61, 152-162.	1.4	40
380	Agreement of efficacy assessments for fiveâ€grass pollen sublingual tablet immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 166-171.	5.7	49
381	†Well days' after sublingual immunotherapy with a highâ€dose 6â€grass pollen preparation. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1104-1105.	5 . 7	7
382	Lowâ€dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1588-1596.	5.7	95
383	Association of the <i>tollâ€like receptor 2</i> Aâ€16934T promoter polymorphism with severe atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1608-1615.	5.7	97
384	Evidence for Novel Tomato Seed Allergens: IgE-Reactive Legumin and Vicilin Proteins Identified by Multidimensional Protein Fractionationa Mass Spectrometry and in Silico Epitope Modeling. Journal of Proteome Research, 2009, 8, 1111-1122.	3.7	45
385	Induction of long-lived allergen-specific plasma cells by mucosal allergen challenge. Journal of Allergy and Clinical Immunology, 2009, 124, 819-826.e4.	2.9	98
386	Management von Handekzemen Leitlinie ICD-10-Ziffer: L20. L23. L24. L25. L30 JDDG - Journal of the German Society of Dermatology, 2009, 7, s1-s16.	0.8	60
387	VertrÄ g lichkeit der spezifischen Immuntherapie wÄ h rend der Umstellung von lyophilisiertem Wespengift auf ein DepotprÄ p arat. Allergologie, 2009, 32, 143-145.	0.1	3
388	In-vitro-Diagnostik und molekulare Grundlagen von IgE-vermittelten Nahrungsmittelallergien. Allergologie, 2009, 32, 177-194.	0.1	7
389	Nahrungsmittelallergie. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2009, , 531-539.	0.0	0
390	Food Allergy in Adults: An Over- or Underrated Problem? Stringent Elimination Diet. Deutsches Ärzteblatt International, 2009, 106, 115; author reply 115-6.	0.9	0
391	Allergy vaccination with peptidesSIT with major cat allergen Fel d 1 peptides: safety, tolerability and dose responses., 2009, 96, 349-53; discussion 353-4.		0
392	Impact of gender on asthma in childhood and adolescence: a GA ² LEN review. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 47-57.	5.7	448
393	1,25â€dihydroxyvitamin D ₃ promotes ILâ€10 production in human B cells. European Journal of Immunology, 2008, 38, 2210-2218.	2.9	277
394	Allergological approach to drug hypersensitivity reactions. JDDG - Journal of the German Society of Dermatology, 2008, 6, 240-243.	0.8	28
395	Systemic PPARÎ ³ Ligation Inhibits Allergic Immune Response in the Skin. Journal of Investigative Dermatology, 2008, 128, 2211-2218.	0.7	54
396	Effects of advanced glycation end productsâ€inductor glyoxal and hydrogen peroxide as oxidative stress factors on rat retinal organ cultures and neuroprotection by UKâ€14,304. Journal of Neurochemistry, 2008, 106, 1876-1887.	3.9	19

#	Article	IF	Citations
397	Insulin allergy: clinical manifestations and management strategies. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 148-155.	5.7	127
398	Care of anaphylaxis among practising doctors. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 1562-1563.	5.7	19
399	Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial. British Journal of Dermatology, 2008, 158, 786-792.	1.5	78
400	The German Multicentre Study on Multiple Chemical Sensitivity (MCS). International Journal of Hygiene and Environmental Health, 2008, 211, 658-681.	4.3	47
401	The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology, 2008, 47, 1185-1192.	1.9	252
402	Fatty acid composition of serum lipid classes in mice following allergic sensitisation with or without dietary docosahexaenoic acid-enriched fish oil substitution. British Journal of Nutrition, 2008, 99, 1239-1246.	2.3	13
403	Variants in a Novel Epidermal Collagen Gene (COL29A1) Are Associated with Atopic Dermatitis. PLoS Biology, 2007, 5, e242.	5.6	153
404	Differential Immunomodulating Effects of Inactivated Probiotic Bacteria on the Allergic Immune Response. Acta Dermato-Venereologica, 2007, 87, 305-311.	1.3	21
405	Penetration of Pollen Proteins into the Skin. Skin Pharmacology and Physiology, 2007, 20, 297-304.	2.5	34
406	Classical conditioning and expectancy in placebo hypoalgesia: A randomized controlled study in patients with atopic dermatitis and persons with healthy skin. Pain, 2007, 128, 31-39.	4.2	130
407	Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5–grass pollen tablet for seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology, 2007, 120, 1338-1345.	2.9	457
408	A cold-response index for the assessment of Raynaud's phenomenon. Journal of Dermatological Science, 2007, 45, 113-120.	1.9	23
409	Role of vitamin A elimination or supplementation diets during postnatal development on the allergic sensitisation in mice. Molecular Nutrition and Food Research, 2007, 51, 1173-1181.	3.3	22
410	Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 184-9.	5.7	77
411	Eczematous reactions to food in atopic eczema: position paper of the EAACI and GA ² LEN. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 723-728.	5.7	182
412	PPAR? expression profile and its cytokine driven regulation in atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 926-933.	5.7	27
413	Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-? antagonists. British Journal of Dermatology, 2007, 156, 486-491.	1.5	240
414	Patch testing in children? recommendations of the German Contact Dermatitis Research Group (DKG). JDDG - Journal of the German Society of Dermatology, 2007, 5, 107-109.	0.8	69

#	Article	IF	Citations
415	Epikutantestung bei Kindern ? Empfehlungen der Deutschen Kontaktallergiegruppe (DKG). JDDG - Journal of the German Society of Dermatology, 2007, 5,	0.8	1
416	A 7-step consultation plan for health care workers and hairdressers. JDDG - Journal of the German Society of Dermatology, 2007, 5, 756-760.	0.8	10
417	Colophony-induced contact dermatitis due to ECG electrodes in an infant. Contact Dermatitis, 2007, 56, 177-178.	1.4	12
418	Recommendation: Dermatologist's procedure JDDG - Journal of the German Society of Dermatology, 2007, 5, 1146-1148.	0.8	30
419	Treatment of atopic dermatitis with pimecrolimus - impact on quality of life. Therapeutics and Clinical Risk Management, 2007, 3, 1021-6.	2.0	5
420	Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. Journal of Allergy and Clinical Immunology, 2006, $118,866-871$.	2.9	352
421	Cytokine and Ig-production by CG-containing sequences with phosphorodiester backbone and dumbbell-shape. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 56-63.	5.7	35
422	Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multiâ€centre, randomized, dose–response study. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 202-205.	5.7	256
423	Type-IV sensitization profile of individuals with atopic eczema: results from the Information Network of Departments of Dermatology (IVDK) and the German Contact Dermatitis Research Group (DKG). Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 611-616.	5.7	70
424	Prospective safety analysis of an ultrarush specific immunotherapy in adults with wasp venom allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 1237-1238.	5.7	9
425	Allergies and the skin, an interdisciplinary approach in GA2LEN and EAACI activities. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 1373-1376.	5.7	10
426	Sublingual immunotherapy. JDDG - Journal of the German Society of Dermatology, 2006, 4, 428-434.	0.8	2
427	Sublinguale Immuntherapie. JDDG - Journal of the German Society of Dermatology, 2006, 4, no.	0.8	0
428	Modulation of lymphocyte phenotype and function by immunoglobulins. British Journal of Dermatology, 2006, 154, 225-230.	1.5	4
429	Infrared-monitored cold response in the assessment of Raynaud's phenomenon Clinical and Experimental Dermatology, 2006, 31, 6-12.	1.3	25
430	Neutrophil respiratory burst is decreased in scleroderma and normalized by near-infrared mediated hyperthermia. Clinical and Experimental Dermatology, 2006, 31, 799-806.	1.3	14
431	Efficacy of topical tacrolimus in the treatment of various cutaneous manifestations of lupus erythematosus. International Journal of Dermatology, 2006, 45, 84-85.	1.0	11
432	Development of Alopecia Areata Universalis in a Patient Receiving Adalimumab. Archives of Dermatology, 2006, 142, 1654-5.	1.4	67

#	Article	lF	CITATIONS
433	New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor antagonists. Annals of the Rheumatic Diseases, 2006, 65, 405-407.	0.9	113
434	Frequency of atopic dermatitis and relevance of food allergy in adults in Germany. Acta Dermato-Venereologica, 2006, 86, 119-22.	1.3	30
435	Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergologie, 2006, 29, 135-156.	0.1	9
436	Negativliste: HautirritabilitÃts- und Hautfunktionsdiagnostik zur Erfassung und Bewertung irritativer HautschÃten. Dermatologie in Beruf Und Umwelt, 2006, 54, 108-111.	0.5	25
437	Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis. European Annals of Allergy and Clinical Immunology, 2006, 38, 355-60.	1.0	20
438	Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nature Medicine, 2005, 11, 1118-1124.	30.7	436
439	Infrared-Mediated Hyperthermia Is Effective in the Treatment of Scleroderma-Associated Raynaud's Phenomenon. Journal of Investigative Dermatology, 2005, 125, 1313-1316.	0.7	15
440	Quantitative patch and repeated open application testing in methyldibromo glutaronitrileâ€sensitive patients. Contact Dermatitis, 2005, 52, 197-206.	1.4	50
441	Retinoic acid inhibits CD40 plus IL-4 mediated IgE production through alterations of sCD23, sCD54 and IL-6 production. Inflammation Research, 2005, 54, 113-118.	4.0	23
442	Introducing Genetic Testing for Adult-Type Hypolactasia. Digestion, 2005, 71, 245-250.	2.3	37
443	Detection of Doxorubicin in the Horny Layer in a Patient Suffering from Palmar-Plantar Erythrodysaesthesia. Dermatology, 2005, 210, 237-238.	2.1	12
444	Modulation of Cytokine Production by Low and High Retinoid Diets in Ovalbumin-Sensitized Mice. International Journal for Vitamin and Nutrition Research, 2004, 74, 279-284.	1.5	25
445	Long-Term Efficacy and Safety of Pimecrolimus Cream 1% in Adults with Moderate Atopic Dermatitis. Dermatology, 2004, 208, 365-372.	2.1	99
446	Food allergy and nonâ€allergic food hypersensitivity in children and adolescents. Clinical and Experimental Allergy, 2004, 34, 1534-1541.	2.9	239
447	Frequency of contact allergy in German children and adolescents patch tested between 1995 and 2002: results from the Information Network of Departments of Dermatology and the German Contact Dermatitis Research Group. Contact Dermatitis, 2004, 51, 111-117.	1.4	116
448	Prevalence of adverse reactions to food in Germany – a population study. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 338-345.	5.7	311
449	Immunoglobulin Eâ€reactivity of wheatâ€allergic subjects (baker's asthma, food allergy, wheatâ€dependent,) Tj Molecular Nutrition and Food Research, 2004, 48, 380-389.	ETQq1 1 0 3.3	0.784314 rgB 70
450	New compounds for the treatment of eczematous skin diseases. Expert Opinion on Therapeutic Patents, 2004, 14, 1257-1271.	5.0	0

#	Article	IF	Citations
451	Klinischer Hautzustand bei BeschÄftigten im Gesundheitswesen und der EinfluÄŸ von PrĤentionsmağnahmen. Dermatologie in Beruf Und Umwelt, 2004, 52, 26-32.	0.5	1
452	Retinoid―and carotenoidâ€enriched diets influence the ontogenesis of the immune system in mice. Immunology, 2003, 110, 180-187.	4.4	47
453	Inhibition of IgE-Production by Peroxisome Proliferator-Activated Receptor Ligands. Journal of Investigative Dermatology, 2003, 121, 757-764.	0.7	29
454	Allergen-mediated modulation of CD23 expression is interferon- \hat{l}^3 and interleukin-10 dependent in allergic and non-allergic individuals. Clinical and Experimental Allergy, 2003, 33, 1568-1575.	2.9	14
455	Wasp Venom Rush Immunotherapy Induces Transient Downregulation of BÂCell Surface Molecule Expression. International Archives of Allergy and Immunology, 2002, 127, 226-233.	2.1	14
456	Aromatic components of food as novel eliciting factors of pseudoallergic reactions in chronic urticaria. Journal of Allergy and Clinical Immunology, 2002, 109, 343-348.	2.9	85
457	Role of Adverse Reactions to Food in Urticaria and Exercise-Induced Anaphylaxis. International Archives of Allergy and Immunology, 2002, 129, 19-26.	2.1	31
458	New compounds for the treatment of eczematous skin diseases. Expert Opinion on Therapeutic Patents, 2002, 12, 1023-1033.	5.0	0
459	Hypersensitivity Reactions to Oxaliplatin: Cross-Reactivity to Carboplatin and the Introduction of a Desensitization Schedule. Journal of Clinical Oncology, 2002, 20, 1146-1147.	1.6	82
460	1?,25-dihydroxyvitamin?D3 inhibits anti-CD40 plus IL-4-mediated IgE productionin vitro. European Journal of Immunology, 2002, 32, 3395-3404.	2.9	71
461	A combination of wheatflour, ethanol and food additives inducing FDEIA. Allergy: European Journal of Allergy and Clinical Immunology, 2002, 57, 1090-1091.	5.7	35
462	Ethanol as a cause of hypersensitivity reactions to alcoholic beverages. Clinical and Experimental Allergy, 2002, 32, 1231-1235.	2.9	32
463	Inhibition of IgE Production by the Imidazoquinoline Resiquimod in Nonallergic and Allergic Donors. Journal of Investigative Dermatology, 2002, 119, 1059-1064.	0.7	36
464	1α,25-dihydroxyvitamin D3 inhibits anti-CD40 plus IL-4-mediated IgE production in vitro. European Journal of Immunology, 2002, 32, 3395-3404.	2.9	103
465	Novel therapies for atopic eczema. Current Opinion in Investigational Drugs, 2002, 3, 1596-603.	2.3	5
466	Sugar is Not an Aggravating Factor in Atopic Dermatitis. Acta Dermato-Venereologica, 2001, 81, 282-284.	1.3	20
467	Increased leukotriene production by food additives in patients with atopic dermatitis and proven food intolerance. Clinical and Experimental Allergy, 2001, 31, 265-273.	2.9	33
468	Effects of Retinoids on in vitro and in vivo IgE Production. International Archives of Allergy and Immunology, 2001, 124, 233-236.	2.1	29

#	Article	IF	CITATIONS
469	Novel Unconventional Therapeutic Approaches to Atopic Eczema. Dermatology, 2000, 201, 191-195.	2.1	30
470	Clinical relevance of food additives in adult patients with atopic dermatitis. Clinical and Experimental Allergy, 2000, 30, 407-414.	2.9	76
471	Expression and Functional Role of Co-stimulatory Molecules in CD40+IL-4-Stimulated B Cells from Atopic and Non-atopic Donors. Acta Dermato-Venereologica, 2000, 80, 287-291.	1.3	7
472	Gelatin-induced Urticaria and Anaphylaxis after Tick-borne Encephalitis Vaccine. Acta Dermato-Venereologica, 2000, 80, 232-232.	1.3	10
473	Evidence for a disease-promoting effect of Staphylococcus aureus–derived exotoxins in atopic dermatitis. Journal of Allergy and Clinical Immunology, 2000, 105, 814-819.	2.9	283
474	Nevoid Bag-Like Soft Fibromas. Dermatology, 1999, 199, 167-168.	2.1	3
475	Evaluation of Systemic Provocation Tests in Patients with Suspected Allergic and Pseudoallergic Drug Reactions. Acta Dermato-Venereologica, 1999, 79, 139-142.	1.3	15
476	Perioral contact dermatitis caused by L-carvone in toothpaste. Contact Dermatitis, 1998, 38, 338-338.	1.4	21
477	Lymphotoxinâ€Î± is an important autocrine factor for CD40+interleukinâ€4â€mediated Bâ€cell activation in normal and atopic donors. Immunology, 1998, 94, 395-402.	4.4	19
478	Hypocomplementaemic urticarial vasculitis: successful treatment with cyclophosphamide-dexamethasone pulse therapy. British Journal of Dermatology, 1998, 139, 704-707.	1.5	39
479	Retinoic Acid Inhibits CD40 + Interleukin-4–Mediated IgE Production In Vitro. Blood, 1998, 92, 1713-1720.	1.4	63
480	Retinoic acid inhibits CD40 + interleukin-4-mediated IgE production in vitro. Blood, 1998, 92, 1713-20.	1.4	18
481	Molecular regulation of human IgE synthesis. Journal of Molecular Medicine, 1997, 75, 440-447.	3.9	44
482	CD40â€"CD40 ligand (CD40L) interactions and X-linked hyperlgM syndrome (HIGMX-1). Clinical Immunology and Immunopathology, 1995, 76, S208-S213.	2.0	23
483	CD40-mediated lymphotoxin α expression in human B cells is tyrosine kinase dependent. European Journal of Immunology, 1995, 25, 2438-2444.	2.9	20
484	Interferon-gamma downregulates epidermal growth factor receptors on human melanoma cells. Experimental Dermatology, 1995, 4, 30-35.	2.9	13
485	Activation of Tumor Necrosis Factor-α and Lymphotoxin-α via Anti-CD40 in Human B Cells. International Archives of Allergy and Immunology, 1995, 107, 368-369.	2.1	11
486	CD40 ligation induces lymphotoxin α gene expression in human B cells. International Immunology, 1994, 6, 1883-1890.	4.0	63

#	Article	IF	CITATIONS
487	Expression of growth factor receptors on human melanoma cells: Comparison of modulating effects of interferons and retinoids. Experimental Dermatology, 1993, 2, 217-223.	2.9	10
488	Determination of granulocyte/macrophage-colony-stimulating factor secretion by human melanoma cells and its effects on human melanoma cell proliferation. Journal of Cancer Research and Clinical Oncology, 1993, 119, 501-503.	2.5	4
489	Anaphylaxie: Wie richtig handeln?., 0, , .		1
490	Nahrungsmittelallergie: Wenn das Essen krank macht., 0,,.		0
491	COVID-19-Impfung: RisikoabschÃtzung aus allergologischer Sicht. , 0, , .		0